DAC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
As part of the in-universe viral marketing campaign, a series of video segments for the series started to be released in the form of in-universe news reports from Vought News Network—a parody of the Cable News Network (CNN) as well as Fox News—called Vought News Network: Seven on 7 with Cameron Coleman through the Vought International YouTube channel. The video segments were released on the seventh day of each month over a period of seven months starting on July 7, 2021, and concluding on January 7, 2022. The video segments served as a bridge between seasons two and three, with each segment containing different stories that tease a series of events expected to happen on upcoming episodes and introducing new characters. Matthew Edison joined the series as Vought News Network anchor Cameron Coleman, a role that he would reprise in the series' third and fourth seasons. The character has also been reported to be a parody of Tucker Carlson. On May 13, 2022, it was released a faux poster for the in-universe fictional film Payback with every member of the superhero group in it with Soldier Boy at the front and center of the poster and the other members surrounding him from behind, serving as a parody and reference of The Avengers film series.
== Treatment == Stopping high vitamin A intake is the standard treatment. Most people fully recover. Phosphatidylcholine (in the form of PPC or DLPC), the substrate for lecithin retinol acyltransferase, which converts retinol into retinyl esters (the storage forms of vitamin A). Vitamin E may alleviate hypervitaminosis A. Liver transplantation may be a valid option if no improvement occurs. If liver damage has progressed into fibrosis, synthesizing capacity is compromised and supplementation can replenish PC. However, recovery is dependent on removing the causative agent: halting high vitamin A intake.
anaphase lag The failure of one or more pairs of sister chromatids or homologous chromosomes to properly migrate to opposite sides of the cell during anaphase of mitosis or meiosis due to a defective spindle apparatus. Consequently, both daughter cells are aneuploid: one is missing one or more chromosomes (creating a monosomy) while the other has one or more extra copies of the same chromosomes (creating a polysomy).
=== Nucleobase classification === The nucleobases are classified into two types: the purines, A and G, which are fused five- and six-membered heterocyclic compounds, and the pyrimidines, the six-membered rings C and T. A fifth pyrimidine nucleobase, uracil (U), usually takes the place of thymine in RNA and differs from thymine by lacking a methyl group on its ring. In addition to RNA and DNA, many artificial nucleic acid analogues have been created to study the properties of nucleic acids, or for use in biotechnology.
Sources: en.wikipedia.org
== Experimental validation == IDPs can be validated in several contexts. Most approaches for experimental validation r and of IDPs are restricted to extracted or purified proteins. Some new experimental strategies aim to explore in vivo conformations and structural variations of IDPs inside intact living cells and systematic comparisons between their dynamics in vivo and in vitro. (In the study of IDPs, the term in vivo is used a little differently from the ordinary meaning of in vivo: it refers to the state as found in living cells, not necessarily the entire living organism, as opposed to the traditional cell-free method of study.)
10 Ca(OH)2 + 6 H3PO4 → Ca10(PO4)6(OH)2 + 18 H2O The ability to synthetically replicate hydroxyapatite has invaluable clinical implications, especially in dentistry. Each technique yields hydroxyapatite crystals of varied characteristics, such as size and shape. These variations have a marked effect on the biological and mechanical properties of the compound, and therefore these hydroxyapatite products have different clinical uses.
== Biological role == In general, aminopeptidases play an important role in the metabolism of both proteins and peptides. Aminopeptidases in the gastrointestinal tract, such as APN and APA, are essential for the digestion of dietary proteins. They facilitate the absorption and utilization of amino acids by cleaving them from the N-terminus of peptides. These enzymes also play a role in the metabolism of bioactive peptides, including hormones and growth factors. By regulating the levels of these peptides, aminopeptidases contribute to homeostasis and physiological process modulation.
Sources: en.wikipedia.org
Considering its composition in practical physiological and psychological terms, "it consists of pre-existent forms, the archetypes, which can only become conscious secondarily and which give definite form to certain psychic contents." Jung writes about causal factors in personal psychology as stemming from, influenced by an abstraction of the impersonal physical layer, the common and universal physiology among all humans.He considers that science would hardly deny the existence and basic nature of "instincts", existing as a whole set of motivating urges. The collective unconscious acts as the frame where science can distinguish individual motivating urges, thought to be universal across all individuals of the human species, while instincts are present in all species. Jung contends, "The hypothesis of the collective unconscious is, therefore, no more daring than to assume there are instincts." The collective unconscious is made up of archetypes.
COVID-19 apps include mobile-software applications for digital contact-tracing—i.e. the process of identifying persons ("contacts") who may have been in contact with an infected individual—deployed during the COVID-19 pandemic. Numerous tracing applications have been developed or proposed, with official government support in some territories and jurisdictions. Several frameworks for building contact-tracing apps have been developed. Privacy concerns have been raised, especially about systems that are based on tracking the geographical location of app users. Less overtly intrusive alternatives include the co-option of Bluetooth signals to log a user's proximity to other cellphones. (Bluetooth technology has form in tracking cell-phones' locations.)) On 10 April 2020, Google and Apple jointly announced that they would integrate functionality to support such Bluetooth-based apps directly into their Android and iOS operating systems. India's COVID-19 tracking app Aarogya Setu became the world's fastest growing application—beating Pokémon Go—with 50 million users in the first 13 days of its release. (Full article...)
== Honors and awards == Dyson was elected a Fellow of the Royal Society (FRS) in 1952. Dyson was elected to the American Academy of Arts and Sciences in 1958. Dyson was elected to the United States National Academy of Sciences in 1964. Dyson was awarded the Dannie Heineman Prize for Mathematical Physics in 1965, Lorentz Medal in 1966, Max Planck Medal in 1969, the J. Robert Oppenheimer Memorial Prize in 1970, the Harvey Prize in 1977 and Wolf Prize in 1981. Dyson was elected to the American Philosophical Society in 1976. In 1986, Dyson received the Golden Plate Award of the American Academy of Achievement. In 1989, Dyson was elected as an Honorary Fellow of Trinity College, University of Cambridge. In 1990, Dyson taught at Duke University as a Fritz London Memorial Lecturer. Dyson published a number of collections of speculations and observations about technology, science, and the future. In 1996, he was awarded the Lewis Thomas Prize for Writing about Science. In 1993, Dyson was given the Enrico Fermi Award. In 1995, he gave the Jerusalem-Harvard Lectures at the Hebrew University of Jerusalem, sponsored jointly by the Hebrew University and Harvard University Press that grew into the book Imagined Worlds. In 2000, Dyson was awarded the Templeton Prize for Progress in Religion. In 2003, Dyson was awarded the Telluride Tech Festival Award of Technology in Telluride, Colorado. In 2011, Dyson received as one of twenty distinguished Old Wykehamists at the Ad Portas celebration, the highest honor that Winchester College bestows. In 2011, Dyson received the Arthur C.
== Motive == No motive was established in court, and none is required for a conviction. Prosecutors suggested several possible explanations, including boredom, thrill‑seeking and "playing God". They also stated that Letby had formed an inappropriate emotional attachment to a married doctor involved in some of the cases, citing frequent text exchanges and a note found in her home containing phrases such as "I trusted you with everything and loved you", "You were my best friend" and "Please help me". Letby denied that she had a relationship with, or feelings for, the doctor. Commentators drew comparisons with the Beverley Allitt case. The former detective who led the Allitt investigation suggested that Letby might have imitated Allitt's methods. Criminal psychologists Dominic Wilmott and David Holmes proposed that Letby could have been motivated by factitious disorder imposed on another, a theory also raised in relation to Allitt.31:15 David Wilson, an emeritus professor of criminology, argued in an August 2023 opinion piece that Letby was driven by a "hero complex".
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.